• ZhiRong Liu, Yaxuan Wang, Jingxin Yan, Junhong Liu, Bing Chen, LuShun Zhang, and Li Cheng.
• Department of General Surgery, Chengdu Second People's Hospital, Chengdu, China.
• J Eval Clin Pract. 2020 Feb 1; 26 (1): 262-271.

Rationale, Aims, And ObjectivesCurrent meta-analysis was conducted aiming to assess the efficacy and safety of recombinant human interleukin-11 (rhIL-11) in the treatment of acute leukaemia (AL) patients with chemotherapy-induced thrombocytopenia (CIT).MethodsWe searched PubMed, Embase, Chinese National Knowledge Infrastructure database (CNKI), Cochrane Library, and Wan Fang Database on 4 July 2018.ResultsTen randomized controlled trials (RCTs) and two observational studies were included, which involved 754 AL patients with CIT. Pooled analysis demonstrated that rhIL-11 was beneficial on CIT: recovery time of platelet count to 50 × 109 /L [weight mean difference (WMD) = -4.19 days; 95% CI: -5.01, -3.37], recovery time of platelet count to 100 × 109 /L (WMD = -4.45 days; 95% CI: -4.85, -4.06), platelet transfusion volume (WMD = -6.14 U; 95% CI: -9.20, -3.09), and the rate of haemorrhage (RR = 0.46; 95% CI: 0.36 to 0.61). Most adverse events associated with rhIL-11 were mild to moderate.ConclusionOur findings suggest that rhIL-11 is effective and safe in the treatment of CIT in patients with AL.© 2019 John Wiley & Sons, Ltd.

15 keywords...

hide…